

The Gastrointestinal Cancers Symposium

January 19-21, 2012

COSPONSORED BY



American Society of Clinical Oncology



Richard M. Goldberg, MD

Chair, 2012 Gastrointestinal Cancers Symposium Steering Committee



Dr. Richard Goldberg is an internationally renowned gastrointestinal oncologist who specializes in colorectal cancer and is a tenured professor in the Department of Internal Medicine at The Ohio State University. He also serves as physician-in-chief at Ohio State's Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and is associate director for the cancer center's outreach programs.

Dr. Goldberg is an honors graduate from Harvard University, where he received a bachelor's degree in biology. He earned his medical degree in 1979 from Upstate Medical University in Syracuse, New York, and then completed his internal medicine residency at Emory University Hospitals and an oncology fellowship at Georgetown University's Vincent T. Lombardi Cancer Research Center.

He began his career at Geisinger Medical Center in Danville, Pennsylvania, as an associate in medical oncology and later as an associate and vice chairman of the Department of Medicine. In 1994, Dr. Goldberg became a consultant in medical oncology at the Mayo Clinic, where he chaired the Gastrointestinal Cancer Research Program for the Mayo Clinic Cancer Center. In 2003, he moved to the University of North Carolina at Chapel Hill as chief of the Division of Hematology and Oncology and associate director for clinical research of the Lineberger Comprehensive Cancer Center. He directed the oncology service line for the UNC Health System and became the inaugural physician-in-chief when the North Carolina Cancer Hospital opened in 2009. At UNC he held the Richard M. Goldberg Distinguished Professorship of Gastrointestinal Cancer Research.

Dr. Goldberg's clinical interests include colorectal and other gastrointestinal (GI) cancers, carcinoid and GI tract neuroendocrine tumors, new drug development and inherited predisposition to GI cancers. His research focuses on clinical studies in patients with GI cancers (principally colorectal), translational studies with laboratory collaborators on biologic specimens from patients with cancer, development of new cancer drugs and drug combinations, and clinical trials methodology. He led a national intergroup study N9741 as part of an international Phase III study of oxaliplatin, irinotecan and 5-fluorouracil in combinations for first-line treatment of advanced colorectal cancer. This study, which resulted in the approval of oxaliplatin for clinical use, was conducted in centers across the United States and Canada and helped change the standard of care for patients with advanced colorectal cancer.

Dr. Goldberg has more than 400 peer-reviewed publications in the areas of gastrointestinal cancer and drug therapy. He serves or has served on editorial boards of major journals such as the *Journal of Clinical Oncology*, *Clinical Colorectal Cancer*, and *The Oncologist*, and he is section editor for GI Cancer for *UpToDate*. He also is the elected chair and CEO of ARCAD US Foundation, co-chair of the Society of Translational Oncology, associate group chair for CALGB, and past president of the International Society of Gastrointestinal Oncology. He has been listed in *US News and World Report's* "Top Doctors" and is ranked among the top one percent in his specialty. He has also been listed in *Who's Who in Medical Sciences Education* and in *Best Doctors* since 2001.

2318 Mill Road, Suite 800
Alexandria, VA 22314

571-483-1300
fax: 571-366-9530